Revisit Every OncLive On Air Episode From February 2026

In case you missed any, below is a recap of the episodes of OncLive On Air® that aired in February 2026. Check out our podcast page for a full episode lineup and to stay up to date with all the latest releases!

Innovation, Equity, and the Future of Oncology: World Cancer Day Spotlight With Deb Schrag, MD, MPH

In this episode of OncLive On Air, Deb Schrag, MD, MPH, of Memorial Sloan Kettering Cancer Center in New York, New York, highlighted the significance of standardizing cancer care, noted the importance of addressing inequities related to treatment access and outcomes, and explained how the oncology community can collaborate to translate advances in cancer treatment to all patients.

“[One of my priorities] is helping us embrace artificial intelligence,” Schrag explained. “It's coming at us fast and furious. It's powerful. It's exciting. It's daunting. And it's a rapid pace of change. It has incredible potential, but the global oncology workforce has to figure out how to meet the moment to use it for all aspects of our mission: care delivery, teaching, training, discovery, and efficiency.”

Targeted Therapies Take Center Stage for Estrogen Receptor–Positive Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

In this episode, Aditya Bardia, MD, MPH, FASCO, of the UCLA Health Jonsson Comprehensive Cancer Center in Los Angeles, California, noted top data from the phase 3 lidERA Breast Cancer study (NCT04961996) of giredestrant (GDC-9545) vs standard endocrine therapy in patients with estrogen receptor (ER)–positive, HER2-negative early breast cancer. He also highlighted the potential clinical significance of the ongoing phase 3 INAVO123 trial (NCT06790693) of inavolisib (Itovebi) plus CDK4/6 inhibitors and letrozole in patients with endocrine-sensitive, PIK3CA-mutated breast cancer.

“If [giredestrant] becomes FDA approved, it’ll provide a novel endocrine therapy option for patients with stage I to stage III ER-positive, HER2-negative, localized breast cancer,” Bardia emphasized.

Third-Line Treatment Selection in mCRC Is Shaped By Recalibration of Patient Priorities and Molecular Retesting: With Christopher Lieu, MD

In this episode, Christopher Lieu, MD, of the University of Colorado Cancer Center in Aurora, noted the process of redefining treatment priorities to factor in evolving care goals when a patient with metastatic colorectal cancer (mCRC) reaches the third-line treatment setting; spotlighted the importance of molecular retesting in this setting to identify new actionable mutations; and explained how shifting effective therapies earlier in the treatment course may reduce the need for third-line options in the future.

"Whenever we map out the third-line strategy for a patient with refractory mCRC, the biggest focus is on how our patient is doing, what their performance status is, and what some of the toxicities [are] that they’ve received from their prior therapies. We also want to take a good look at their molecular information,” Lieu stated.

Comprehensive Ph+ ALL Paradigm Knowledge Informs Frontline Ponatinib Use: With Nicholas Short, MD

In this episode, Nicholas Short, MD, of The University of Texas MD Anderson Cancer Center in Houston, highlighted the evolution of treatment considerations for patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) and explained how the TKI ponatinib (Iclusig) compares with other agents in its class for the management of Ph-positive ALL.

“The paradigm has shifted to commonly chemotherapy-free regimens with blinatumomab (Blincyto),” Short explained. “We're usually giving blinatumomab and ponatinib. We can now treat these patients with chemotherapy-free regimens and avoid chemotherapy for patients, which they appreciate. The data so far look like the outcomes are at least as good as [those with] intensive chemotherapy. It looks like [the data with blinatumomab] are probably better, although we'll need longer follow-up and larger studies to get a better idea of that.”

How Patient Prioritization Paved the Way for a Legacy of Oncology Care: With D. Ross Camidge, MD, PhD; and Robert Kantor, MD

In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, was joined by Robert Kantor, MD, of Private Health Management, to discuss Dr Kantor’s prolific career across oncology practice models and his current clinical oversight role, where he guides patients in the direction of cutting-edge therapies most suited to their needs.

“I’m a medical oncologist and hematologist in practice in the Denver area for 32 years, focusing on having the patients in front of me,” Kantor described. “[I have] prided myself throughout my career about my time spent with my patients and the difference that I hopefully was able to make in the lives of my patients and their families.”

“Training goes on in university systems where the entire people teaching you are academics,” Camidge noted during a portion of the conversation about the limitations of oncology education. “And yet, [approximately] 80% of trainees end up in private practice. We have this slight disconnect between our training system and the reality of the jobs at the end of the day.”

FDA Approval Insights: Subcutaneous Amivantamab for EGFR-Mutated NSCLC: With Alexander I. Spira, MD, PhD, FACP, FASCO

In this episode, Alexander I. Spira, MD, PhD, FACP, FASCO, of the Virginia Cancer Specialists Research Institute in Fairfax, highlighted the significance of the FDA approval of amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for the treatment of patients with EGFR-mutated non–small cell lung cancer (NSCLC) across all approved indications for amivantamab-vmjw (Rybrevant).

“Subcutaneous amivantamab has 2 major advantages,” Spira reported. “One is time. Patients are coming into the office frequently. The intravenous [IV] infusions are a long duration, so it helps clear up chair time from our oncology offices. But more importantly, it's helpful for patients who don't want to spend time with us. They'd rather spend time with loved ones. The other major advantage is decreased risk of infusion-related reactions, which we could get by [with] in our patients with the IV formulation, but could be scary and sometimes challenging to deal with.”

Answering Common Questions About Chondrosarcoma Diagnosis and Management: With Hari Desphande, MD, and Philippos Costa, MD

In this episode, Philippos Costa, MD; and Hari Deshpande, MD, both of the Yale School of Medicine in New Haven, Connecticut, collaborated to present expert-led answers to frequently-asked questions about chondrosarcoma in honor of International Chondrosarcoma Awareness Day, which is observed annually on February 6.

“Similar to other sarcomas, when we were talking about chondrosarcomas, we're talking about a heterogeneous group of diseases,” Costa noted.

“We have had nice advances in the past few months in chondrosarcoma, both in terms of trials available and trials that have given preliminary results,” Desphande added.

ASCO GU 2026 Preview

In this episode of Two Onc Docs, hosts Samantha A. Armstrong, MD, of Indiana University Health in Indianapolis, and Karine Tawagi, MD, of the University of Illinois in Chicago, previewed anticipated data from the 2026 Genitourinary Cancers Symposium, including presentations to keep an eye on in prostate cancer, bladder cancer, and renal cell carcinoma.

“We’re going to hear overall survival data from the phase 2 BRCAAway trial [NCT03012321],” Tawagi highlighted when noting prostate cancer presentations to watch. “These are patients with metastatic castration-resistant prostate cancer, but they have BRCA1/2 or ATM alterations. They were given abiraterone and prednisone with olaparib either concurrently or sequentially. We heard that there was a longer progression-free survival [PFS] if the agents were given together vs alone or sequentially. Although the number of patients who crossed over was small, the frontline combination [elicited] a better PFS compared with sequential therapy. I’m looking forward to more data on that.”

“Whenever you’re giving bone-strengthening drugs like bisphosphonate or denosumab, [you need to get] dental clearance beforehand,” Armstrong added during the prostate cancer discussion. “Also, radium-223 we were always taught was mostly for bone disease. That’s something you will need to know going into boards this year.”

A Thoracic Oncologist’s Journey from Iran to Innovation: With Girindra Raval, MD; and Hossein Borghaei, DO, MS

In this episode of Cancer, Character, and Calling: The Oncologist’s Journey, host Girindra Raval, MD, sat down with Hossein Borghaei, DO, MS, of Fox Chase Cancer Center in Philadelphia, Pennsylvania, to discuss Dr Borghaei’s personal journey into medicine and oncology, highlighting how he got his start in the field, as well as how immigration to the US, mentorship from key colleagues, and scientific curiosity shaped his career and patient care philosophy.

“[There is] power in these emotions and these relationships we build over the years with our patients,” Borghaei shared.

“I wish that when I grew up, I could become a physician like you, who cares so much,” Raval said.

Treatment Evolutions Affect First-Line Chemotherapy Selection in Metastatic Pancreatic Cancer: With Rachna T. Shroff, MD, MS, FASCO; and Kristen Spencer, DO

In this episode, Rachna T. Shroff, MD, MS, FASCO, of the University of Arizona Comprehensive Cancer Center in Tucson, and Kristen Spencer, DO, of the New York University Langone Perlmutter Cancer Center, highlighted the evolution of NALIRIFOX use within the first-line pancreatic cancer treatment paradigm, as well as factors that affect decision-making between standard frontline chemotherapy and clinical trial enrollment for patients with metastatic pancreatic cancer.

“I err toward a clinical trial if a clinical trial is available,” Shroff described. “I tell my patients all the time that the cures of today were from yesterday's clinical trials.”

“[NALIRIFOX] offers us a bit more flexibility in how we tailor our therapy, specifically based on the toxicity profile, as well as the patient’s presenting performance status and symptoms, rather than just making recommendations on efficacy,” Spencer added.

Evolving Standards and Emerging ADCs Redefine Cervical Cancer Care: With Ursula A. Matulonis, MD; and Susana M. Campos, MD, MPH

In this episode of From Discovery to Delivery: Charting Progress in Gynecologic Oncology, host Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, was joined by Susana M. Campos, MD, MPH, of Dana-Farber Cancer Institute, who gave insights on the evolution of management strategies for newly diagnosed cervical cancer, including emerging therapies and epidemiologic trends.

“[We discussed] cervical cancer in general, what trends are happening with this cancer in terms of incidence overall, as well as the incidence in specific age groups, as the 2026 statistics were released recently,” Matulonis summarized.

“This is a preventable disease,” Campos emphasized. “We all see patients with advanced cervical cancer, [but] maybe the human papillomavirus [HPV] vaccine, or screening, could have saved them this unfortunate circumstance. The HPV vaccine is safe and highly effective.”

Positive Phase 3 Data Drive Varegacestat Development in Desmoid Tumors: With Rashmi Chugh, MD

In this episode, Rashmi Chugh, MD, of the University of Michigan Rogel Cancer Center in Ann Arbor, noted current treatment goals and unmet needs for patients with desmoid tumors, the biologic rationale for inhibiting γ-secretase in this disease, and the potential role of varegacestat in the treatment paradigm based on findings from the phase 2/3 RINGSIDE trial (NCT04871282).

“Desmoid tumors are heterogeneous in their behavior and the way they affect different patients at different times in their lives,” Chugh explained. “Sometimes they can be almost a chronic disease that can cause pain or decrease function and affect a patient. In those situations, when we need multiple treatments to help manage desmoid tumors, we do not have as many treatments as we need to try to control the disease, as well as maintain quality of life as long as we'd like.”

Pumitamig Represents Potential Immunotherapy Strategy for TNBC: With Sarah Sammons, MD

In this episode, Sarah Sammons, MD, of Dana-Farber Cancer Institute, spotlighted key data and clinical implications from a phase 2 study (NCT06449222) investigating the PD-L1– and VEGF-A–directed bispecific antibody pumitamig (BNT327/BMS986545) in patients with locally advanced or metastatic triple-negative breast cancer.

“In this study, the overall response rates were identical for the PD-L1–positive and PD-L1–negative populations, showing that we have hope for an immunotherapeutic strategy for our PD-L1–negative patients, who have not had that before,” Sammons summarized.

Six-Year CheckMate 9LA Data Reinforce Durable Survival in Metastatic NSCLC: With David Carbone, MD, PhD

In this episode, David Carbone, MD, PhD, of The Ohio State University Comprehensive Cancer Center–James in Columbus, noted key takeaways from the 6-year findings from the phase 3 CheckMate 9LA trial (NCT03215706), which showed the durability of responses with nivolumab (Opdivo) in combination with ipilimumab (Yervoy) and chemotherapy in the first-line setting in patients with NSCLC, including across historically poor-prognosis subgroups.

“It's fantastic that we have long-term survivals with these regimens,” Carbone noted. “Historically, virtually no patients lived more than 2 or 3 years with chemotherapy. Now, even in the control arm, some patients are living longer, but that's due to crossover, I’m sure. Now that there are multiple first-line regimens approved, my metric for choosing one is no longer something like median survival or response rate. Especially with immunotherapies, what we need to look at is the number of patients alive or dead at 5 or 6 years: the long-term survival.”

Breast Imaging Advances Emphasize the Importance of Patient-Focused Nuclear Medicine Collaboration: With Megan Kruse, MD; and Sophia O’Brien, MD

In this episode, Megan Kruse, MD, of Cleveland Clinic in Ohio, and Sophia O’Brien, MD, of Penn Medicine in Philadelphia, Pennsylvania, presented insights on the use of breast cancer imaging modalities, such as 18F-fluoroestradiol (FES)–PET/CT, in lobular breast cancer and beyond.

"[FES-PET/CT] is helpful at the initial diagnosis of metastatic, ER-positive breast cancer, or at progression before the next line of therapy to help decide what the next line of therapy should be," O’Brien contextualized.

“One area where I think FES-PET/CT scans could be useful moving forward would be in better delineating the extent of cancer in the early-stage breast cancer setting,” Kruse added.